⌕
Spyre Therapeutics · SYRE · Nasdaq
Tenet 43 · Weak
Compare
$93.81−5.60%At closeTenet 43 · Weak
$93.81−5.56 (−5.60%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Spyre Therapeutics (SYRE) Stock

Spyre Therapeutics (SYRE) closed at $93.81 on Nov 17, 2026; its Tenet Score is 43 of 100 against 340 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

41 figures withheld by our checks. Each blank figure names its reason.

Key stats

Close
$93.81
Nov 17, 2026
Market cap
$9.4B
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
22.13 – 110.64
low → high · as of close, Nov 16, 2026
Tenet Score
43/100
Weak · 340 Healthcare peers

Industry: Drugs

Spyre Therapeutics Inc. scores 43/100. Weak. Strongest on financial health, value is the soft spot versus 340 Healthcare peers. Insufficient inputs: Tenet 43 is built from 3 of 4 pillars, from 35% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=340
43/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
16
Quality
21
Health
94
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Growth omitted — no data yet.
ValueFQualityFHealthAGrowth—MomentumA+
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
10.4×
Sep 30, 2026 balance sheet
P/S
—
Not reported in the company's filings for this period.
ROE
−44%
TTM through Sep 30, 2026
Operating margin
—
no operating margin on file
Net margin
—
Not meaningful: revenue is too small to measure a margin against.
Current ratio
27.40
Sep 30, 2026 balance sheet
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Spyre Therapeutics Inc.

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 96 US ETFs · top wrappers by weightSee all ETFs holding SYRE →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 16, 2026.

What sector and industry is Spyre Therapeutics in?

Spyre Therapeutics is in the Healthcare sector and the Drugs industry.

What is Spyre Therapeutics' Tenet Score?

Spyre Therapeutics' Tenet Score is 43 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.